

10-16-00

A



SKJERVEN  
MORRILL  
MACPHERSON LLP

Docket No.: M-9177 US

October 13, 2000

Box Patent Application  
Commissioner For Patents  
Washington, D. C. 20231

Enclosed herewith for filing is a patent application, as follows:

Inventors: Jeffrey L. Cleland, Xanthe M. Lam, and Franklin Okumu  
Title: INJECTION VEHICLE FOR POLYMER-BASED FORMULATIONS

X Return Receipt Postcard  
X This Transmittal Letter (in duplicate)  
27 page(s) Specification(not including claims)  
3 page(s) Claims  
1 page Abstract  
3 page(s) Declaration For Patent Application and Power of Attorney  
1 page(s) Recordation Form Cover Sheet (in duplicate)  
2 page(s) Assignment  
2 Page(s) Preliminary Amendment

**CLAIMS AS FILED**

For	Number Filed		Number Extra		Rate		Basic Fee
Total Claims	20	-20 =	0	x	\$ 18.00	=	\$ 710.00 \$ 0.00
Independent Claims	4	-3 =	1	x	\$80	=	\$ 80.00
<input type="checkbox"/>	Fee of _____ for the first filing of one or more multiple dependent claims per application						\$
<input type="checkbox"/>	Fee for Request for Extension of Time						\$

Please make the following charges to Deposit Account 19-2386:

- ☒ Total fee for filing the patent application in the amount of \$ 790.00  
☒ The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Deposit Account 19-2386.

EXPRESS MAIL LABEL NO:

EL699360860US

Respectfully submitted,

Emily M. Haliday  
Attorney for Applicants  
Reg. No. 38,903

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: Jeffrey L. Cleland, Xanthe M. Lam and Franklin Okumu  
Assignee: Genentech, Inc.  
Title: INJECTION VEHICLE FOR POLYMER-BASED FORMULATIONS  
Serial No.: Not assigned yet Filing Date: October 13, 2000  
Examiner: Not assigned yet Group Art Unit: Not assigned yet  
Docket No.: M-9177 US

San Jose, California

BOX PATENT APPLICATION  
COMMISSIONER FOR PATENTS  
Washington, D. C. 20231

**PRELIMINARY AMENDMENT**

Dear Sir:

Prior to the examination of the above-referenced application, please amend the application as indicated below.

**IN THE SPECIFICATION**

On page 1, line 12, please insert the following paragraph:

**-- CROSS-REFERENCE TO RELATED APPLICATIONS**

This application claims the benefit of U.S. Provisional Application No. 60/159,739 filed October 15, 1999, entitled "INJECTION VEHICLE FOR POLYMER-BASED FORMULATIONS" and naming Jeffrey L. Cleland, Xanthe M. Lam and Franklin Okumu as inventors. This prior application is hereby incorporated by reference in its entirety. - -

LAW OFFICES OF  
SKJERVEN MORRILL  
MACPHERSON LLP

25 METRO DRIVE  
SUITE 700  
SAN JOSE, CA 95110  
(408) 453-9200  
FAX (408) 453-7979

## REMARKS

It is respectfully requested that the Examiner contact the undersigned attorney at (408) 96 with any questions regarding the application.

**Express Mail Label No.:**

**EL699360860US**

Respectfully submitted,

Emily Haliday  
Attorney for Applicants  
Reg. No. 38,903

**LAW OFFICES OF  
SKJERVEN MORRILL  
MACPHERSON LLP**

25 METRO DRIVE  
SUITE 700  
SAN JOSE, CA 95110  
(408) 453-9200  
FAX (408) 453-7979

Docket No: M-9177 US  
Express Mail Label No.: EL699360860US

***UNITED STATES PATENT APPLICATION***

**INJECTION VEHICLE FOR POLYMER-BASED  
FORMULATIONS**

Inventors: **Jeffrey L. Cleland**, a citizen of the United States of America,  
residing at 225 Aberdeen Drive, San Carlos, CA 94070

**Xanthe M. Lam**, a citizen of the United States of America,  
residing at 662 Orchid Drive, South San Francisco, CA 94080

**Franklin Okumu**, a citizen of the United States of America,  
residing at 3882 Shafter Avenue, Oakland, CA 94609

Assignee: Genentech, Inc.

SKJERVEN MORRILL MACPHERSON LLP  
25 Metro Drive, Suite 700  
San Jose, CA 95110  
(408) 453-9200 Tel  
(408) 453-7979 Fax

5 INJECTION VEHICLE FOR POLYMER-BASED FORMULATIONS

FIELD OF THE INVENTION

The invention relates to injection vehicles for particulate suspensions, e.g., polymer-based formulations and associated pharmaceutical formulations and methods. In particular,  
10 the invention relates to injection vehicles, pharmaceutical formulations, and methods that allow the use of smaller-bore needles to inject particulate suspensions.

BACKGROUND OF THE INVENTION

Sustained-release delivery systems for therapeutic agents have received a considerable  
15 amount of attention in recent years. Examples include controlled-release injectable and oral formulations, transdermal patches, and implantable depot formulations. Such systems are of particular interest as a means of delivering therapeutic proteins.

When producing formulations of therapeutic proteins, it is important to preserve the physical, chemical, and biological properties of the protein. In contrast to lower molecular  
20 weight drugs, proteins typically have large globular structures, including secondary, tertiary, and in some cases, quaternary structural features that are important for biological activity. Furthermore, proteins have labile bonds and chemically reactive groups on their side chains which are susceptible to oxidation (methionine, tryptophan, histidine, tyrosine), deamidation (arginine, glutamine) or disulfide reduction or interchange (cysteine). In addition to  
25 preserving biological activity, it is particularly important to reduce or eliminate protein alterations that increase the protein's immunogenicity. Undesired immune responses can lead to safety concerns, and neutralizing antibody responses can limit the efficacy of subsequent treatments. Thus, the need to stabilize therapeutic proteins for long periods in a physiological

environment has been an obstacle to the development of sustained-release protein delivery systems.

One way to stabilize drugs is to embed them in biodegradable polymeric microparticles (Maulding (1987), J. Controlled Release 6:167-176; Smith et al. (1990),  
5 Advanced Drug Delivery Reviews 4:343-357; Holland et al. (1986), J. Controlled Release 4:155-180; Lewis et al. (1990), Biodegradable Polymers as Drug Delivery Systems, pp. 1-41, Dekker, New York.) Studies using microparticles made from homo- and co-polymers of lactic and glycolic acid (PLGA polymers) have shown that these polymers hydrolyze to acid monomers (Maulding (1987), J. Controlled Release 6:167-176; Smith et al. (1990), Advanced  
10 Drug Delivery Reviews 4:343-357; Cower et al. (1985), Methods in Enzymology 112:101-116) and are chemically unreactive under the conditions used to prepare the microparticles. Such polymers can be produced in a range of molecular weights and monomer ratios which allows adjustment of the drug release rate to the particular application. PLGA polymers are non-immunogenic and non-toxic. These properties led to the selection of a PLGA polymer  
15 for use in the depot formulation of the luteinizing hormone releasing hormone (LHRH) agonist luprolide (Sanders et al. (1986), J. Pharm. Sci. 75:356-360; Ogawa et al. (1988), Chem. Pharm. Bull. 5:1095-1103; Ogawa et al. (1988), Chem. Pharm. Bull. 36:2576-2581). Johnson et al. (1997), Pharmaceutical Research 14:730-735, stabilized recombinant human growth hormone by forming a zinc-protein complex and encapsulated the complex in the solid  
20 state into PLGA microparticles (see also PCT Application No. PCT/US95/05511, Publication No. WO 95/29664).

Despite their advantages for stabilizing proteins, the administration of polymer-based drug formulations can be problematic. For example, the dose is limited by the amount of the formulation that can readily be suspended and injected. In formulations containing particles,  
25 aggregation or dilatancy can lead to clogging of the needle, making it difficult to administer the intended dose. In an effort to reduce agglomeration, excipients such as carboxymethylcellulose (CMC), dextran, or sorbitol have been included in the injection vehicle. Surfactants and salts have also been added in an effort to alter the particles' fluid

properties. CMC, Tween<sup>TM</sup>, and phosphate-buffered saline have been used in a vehicle for delivering a lupron depot formulation. However, the doses of this formulation are relatively small: 30-60 mg of microparticles each. In general, it is difficult to inject doses greater than 200 mg/mL of microparticles through a 21- or 23-gauge needle. Assuming a maximum  
5 subcutaneous dose of 1 mL, the maximum microparticle dose is 200 mg. The use of such large-bore needles increases the pain of injection, but the use of smaller bore needles further restricts the dose that can be delivered in a single injection.

An injection vehicle that enhanced the injectability of particulate suspensions, generally, and/or polymer-based drug formulations, in particular, would allow delivery of  
10 higher doses of drug and/or allow the use of smaller needles. These benefits would increase the feasibility of polymer-based formulations for a wider variety of therapeutic applications.

## SUMMARY OF THE INVENTION

The present invention includes a fluid suitable for use in administering a particulate  
15 suspension by injection. This injection vehicle comprises a flexible molecule, such as hyaluronic acid or a derivative thereof, dissolved in a physiological buffer, such as saline. The injection vehicle of the invention allows the injection of higher doses of particulate suspensions, such as polymer-based drug formulations, using smaller needles, than is possible using conventional injection vehicles.

20 The present invention also provides a pharmaceutical formulation including an effective amount of a biologically active agent in the injection vehicle of the invention. The biologically active agent can be in the form of particles, coated onto particles, dispersed within particles, or accompanied by particles in the injection vehicle. Such formulations can be employed to administer biologically active agents for prophylactic, therapeutic, or  
25 diagnostic applications.

In a preferred embodiment, the biologically active agent is a polypeptide dispersed within particles that provide sustained release of the polypeptide. The particles are, preferably, composed of a biocompatible polymer matrix, such as a poly(lactide-co-glycolide)

matrix. Preferred formulations include, for example, a growth hormone, a hepatocyte growth factor (HGF), a vascular endothelial growth factor (VEGF), an anti-VEGF Fab, a glucagon-like peptide I (GLP-I), a nerve growth factor, or an insulin-like growth factor as the biologically active agent.

5           The present invention also encompasses methods for producing and administering the pharmaceutical formulations described herein. In a preferred embodiment, a pharmaceutical formulation according to the invention is administered by injection through a 23-gauge or smaller needle.

10 DETAILED DESCRIPTION OF THE INVENTION

## Definitions

Terms used in the specification and claims are defined as set forth below unless otherwise specified.

The term “injection vehicle” refers to a fluid suitable for use in administering a drug  
15 by injection (e.g., subcutaneous, intramuscular, intravenous, etc.).

The term “pseudoplastic composition” refers to a composition having a viscosity that decreases with increasing shear rate. Shear is the friction that occurs when a plate is moved relative to another plate with a solution between them. Shear rate is the speed at which the plate is moved. Shearing also occurs when a viscous substance flows through a needle, and thus pseudoplasticity affects the ease with which such substances can be injected.

“Hyaluronic acid” is a large, branched mucopolysaccharide molecule with alternating beta (1-3) glucuronide and beta (1-4) glucosamide bonds. As used herein, the term “hyaluronic acid” refers to the form having the same structure as the naturally occurring molecule found in the extracellular matrix of vertebrate connective tissues.

25 A wide variety of chemical modifications of hyaluronic acid are possible. The term “hyaluronic acid derivative” is used herein to refer to a molecule having the hyaluronic acid “backbone” (i.e., the alternating glucuronide and glucosamide bonds) and one or more chemical groups not present in naturally occurring hyaluronic acid. For ease of discussion,



hyaluronic acid and its various derivatives are collectively termed "hyaluronic acids."

Exemplary hyaluronic acids include ester, amide and lactide derivatives. The formation of specific acyl derivatives of hyaluronic acid is described in U.S. Patent 5,527,893. Further, water-insoluble hyaluronic acid derivatives are described in U.S. Patent Nos. 5,017,229 and  
5 4,937,270. Hyaluronic acid has been conjugated to polyethylene glycol, and such "pegylated" forms are also "hyaluronic acids," as this term is used herein. Hyaluronic acids in the form of esters or salts, which are termed "hyaluronates," are conveniently employed in the invention.

The molecular weight of hyaluronic acids vary and therefore references herein to the molecular weight of hyaluronic acids refer to average molecular weights.

10 Concentrations expressed as "percent by volume" or "% (v/v)" are calculated by dividing the volume of the component by the total volume of the composition.

Concentrations expressed as "percent by weight" or "% (w/w)" are calculated by dividing the weight of the component by the total weight of the composition.

Concentrations expressed as "percent weight per volume" or % (w/v) are calculated by  
15 dividing weight (e.g., in grams) by volume (e.g., in liters).

"Viscosity" is a measure of a solution's resistance to flow, typically in units of centistokes (cSt or cs).

"Physiological saline" is defined as a 0.9 percent (weight/volume) sodium chloride in water.

20 A "polymer-based formulation" is defined as a formulation in which a biologically active agent is dispersed within a polymeric matrix.

The term "polymeric matrix" refers to a discontinuous polymeric structure with one or more other materials and/or spaces dispersed throughout.

The term "biocompatible" refers to a material that can be introduced into the human  
25 body in the amounts described herein without significant adverse effects, such as toxicity or immunogenicity. If the material is degraded in vivo, the term also indicates a material whose in vivo degradation products also do not cause significant adverse effects.

The term “biodegradable” refers to compositions that degrade or erode in vivo to form smaller units. Degradation can result from any process occurring in vivo, including enzymatic, chemical, and physical processes.

5 A “blocked polymer” has blocked carboxyl end groups. Generally, the blocking group is derived from the polymerization initiator and is typically an alkyl radical. An “unblocked polymer” has free carboxyl end groups.

The term “microparticles” is used herein to refer to particles having a maximum dimension (i.e., length or diameter) of less than about one millimeter. Microparticles that are substantially spherical and/or ellipsoidal are termed “microspheres.”

10 A “biologically active agent” is defined as an agent having an in vivo activity, typically an activity that confers therapeutic, prophylactic, and/or diagnostic utility.

The terms “proteins” and “polypeptides” are used interchangeably herein.

The term “effective amount” describes an amount of a biologically active agent that produces an in vivo activity.

15 The term “aseptic processing” describes a process of sterilization that involves the sterilization of individual components used in a process or product, followed by processing and packaging activities carried out under aseptic conditions. A variety of conventional methods are used in aseptic processing, depending upon the physical characteristics of the product, its container, and the closure. Exemplary methods include filtration (liquid forms),  
20 dry heat-sterilization (glass components), pressurized steam (rubber components), and radiation and/or treatment with ethylene oxide (plastic components).

The term “terminal sterilization” describes a process whereby a drug product, which may or may not be presterilized, is filled and sealed in a container and then subjected to final sterilization. A number of techniques can be used in terminal sterilization and include, for  
25 example, radiation and autoclaving.

### Injection Vehicle

The invention provides an injection vehicle comprising a pseudoplastic composition. The pseudoplastic composition provides improved injectability, compared with conventional injection vehicles, and is therefore particularly useful for injecting suspensions of particles, such as, for example, polymer-based formulations. Pseudoplastic compositions according to the invention are generally solutions of flexible molecules that deform to an ellipsoid conformation when exposed to shear forces and tend to become aligned in the direction of flow with increasing shear rate. Flexible molecules suitable for use in the present invention are typically, large branched polymeric molecules. Exemplary flexible molecules include hyaluronic acid, hyaluronic acid derivatives, and combinations thereof. Hyaluronic acid is preferred and is conveniently employed in the form of sodium hyaluronate.

Considerations affecting the selection of pseudoplastic compositions include viscosity, molecular weight, and pH. Pseudoplastic compositions suitable for use in the invention are generally viscous enough to allow the polymer component of polymer-based formulations to remain suspended in the injection vehicle during injection. Dynamic viscosities can range from about 1,000 to about 500,000 centistokes (cSt) at a shear rate of 1/second at 25° C and are preferably in the range of about 1,000 to about 100,000 cSt, and more preferably in the range of about 2,000 to about 65,000 cSt.

The viscosity of a solution containing a flexible molecule is a composite function of molecular weight and concentration, as well as the temperature and solvent used. Specifically, viscosity increases with increasing molecular weight and increasing concentration. Flexible molecules suitable for use in the pseudoplastic composition of the invention generally have average molecular weights in the range of about  $0.5 \times 10^5$  to about  $5 \times 10^6$  Daltons although molecules of higher or lower average molecular weight can also be employed. Preferred average molecular weights for hyaluronic acids useful in the invention are between about  $2 \times 10^5$  and about  $5 \times 10^6$  Daltons.

The concentration of flexible molecules is generally between about 0.01 percent to about 10.0 percent weight per volume (w/v), although one skilled in the art appreciates that as

average molecular weight increases, the concentration needed to achieve a particular viscosity decreases. Hyaluronic acids in the preferred size range described above are conveniently employed at a concentration between about 0.01 percent to about 3 percent (w/v), preferably between about 0.1 percent to about 1 percent (w/v), and more preferably less than  
5 0.8 percent (w/v).

The pH of the pseudoplastic composition should generally be close to the physiologic norm of approximately 7.0. Preferred pseudoplastic compositions have a pH in the range of about 5.0 to 7.8.

The pseudoplastic composition can include any solvent capable of dissolving a  
10 flexible molecule, as described above, wherein the resulting solution has a suitable viscosity and pH for use in the invention. One skilled in the art can readily select a suitable solvent for a particular flexible molecule. Aqueous solvents are preferred, and examples include physiological buffers (such as physiological phosphate buffer) and physiological saline.

The pseudoplastic composition of the present invention is generally substantially free  
15 of endotoxin, exotoxin, fungi, precipitates, and the like, which can cause adverse reactions in the recipient. Sterilization of the composition can be achieved by acetic processing or terminal sterilization, using any conventional sterilization technique suitable for the composition. One skilled in the art can readily identify a sterilization technique suitable for a given composition.

20

#### Pharmaceutical Formulations

Pharmaceutical formulations of the invention comprise the injection vehicle of the invention, particles, and a biologically active agent. The particles and the biologically active agent can be a single component (i.e., the biologically active agent can be in particulate form)  
25 or two different components. Examples of the latter include embodiments in which the biologically active agent is coated on, or dispersed within, the particles. Preferred embodiments employ microparticles made up of a polymeric matrix having a biologically active agent dispersed therein. The concentration of particulate/biologically active agent

component(s) depends on the desired dose and the maximum amount of the component(s) that can be injected. For example, polymeric microparticles including a biologically active agent dispersed therein are generally employed at concentrations between about 1 mg/mL and about 500 mg/mL and more preferably between about 50 mg/mL to about 150 mg/mL.

5 In polymer-based formulations, the polymer that forms the polymeric matrix is a biocompatible polymer that can be biodegradable or non-biodegradable, a mixture of biodegradable and non-biodegradable polymers, or a copolymer comprising biodegradable and non-biodegradable units. Suitable biocompatible, biodegradable polymers include, for example, poly(lactide)s, poly(glycolide)s, poly(lactide-co-glycolide)s, poly(lactic acid)s,  
10 poly(glycolic acid)s, poly(lactic acid-co-glycolic acid)s, polyanhydrides, polyorthoesters, polyetheresters, polycaprolactone, polyesteramides, block copolymers of polyethylene glycol and lactide or glycolide, and blends and copolymers thereof.

Biocompatible, non-biodegradable polymers suitable for pharmaceutical compositions of the invention include, for example, non-biodegradable polyacrylates, polymers of ethylene-  
15 vinyl acetates and other acyl-substituted cellulose acetates, non-degradable polyurethanes, polystyrenes, polyvinyl chloride, polyvinyl fluoride, poly(vinyl imidazole), chlorosulphonate polyolefins, polyethylene oxide, and blends and copolymers thereof.

The polymer can be blocked, unblocked, or a blend of blocked and unblocked polymers.

20 Suitable molecular weights for polymers used in the invention can be determined by a person of ordinary skill in the art taking into consideration factors such as the desired polymer degradation rate, and physical properties such as mechanical strength. Typically, polymer molecular weight ranges from about 2,000 Daltons to about 2,000,000 Daltons.

In a preferred embodiment, the polymer is a biodegradable polymer or copolymer. In  
25 a more preferred embodiment, the polymer is a poly(lactide-co-glycolide) (PLGA) with a lactide:glycolide ratio of about 1:1 and a molecular weight of about 5,000 Daltons to about 70,000 Daltons. In an even more preferred embodiment, the PLGA used in the present invention has a molecular weight of about 5,000 Daltons to about 42,000 Daltons.

10

15

20

25

10/15/99 05 15



bFGF; epidermal growth factor (EGF); transforming growth factor (TGF), such as TGF-alpha and TGF-beta, including TGF- $\beta$ 1, TGF- $\beta$ 2, TGF- $\beta$ 3, TGF- $\beta$ 4, or TGF- $\beta$ 5; insulin-like growth factor-I and -II (IGF-I and IGF-II); des (1-3) -IGF-I (brain IGF-I); insulin-like growth factor binding proteins; CD proteins such as CD-3, CD-4, CD-8, and CD-19; erythropoietin;  
5 osteoinductive factors; immunotoxins; a bone morphogenetic protein (BMP); an interferon such as interferon-alpha, -beta, and -gamma; colony stimulating factors (CSFs), such as M-CSF, GM-CSF, and G-CSF; interleukins (ILs), such as IL-1 to IL-10; superoxide dismutase; T-cell receptors; surface membrane proteins; decay accelerating factor; viral antigens, such as, for example, the HIV-1 envelope glycoproteins, gp120, gp160 or fragments  
10 thereof; transport proteins; homing receptors; addressins; regulatory proteins; antibodies, and portions thereof, such as Fab fragments; and chimeric proteins, such as immunoadhesins.

A pharmaceutical formulation according to the invention may also contain more than one biologically active agent, for instance, two different polypeptides.

As discussed above, the biologically active agent can be employed in the form of  
15 particles. Such particles can include, for example, crystalline particles, non-crystalline particles, freeze-dried particles, lyophilized particles, and combinations thereof. The particles may contain only the biologically active agent or may also contain a stabilizing agent and/or other excipient. The particles can be employed as free particles dispersed throughout the pharmaceutical formulation or, in a preferred embodiment, dispersed throughout the polymer  
20 matrices in polymer-based formulations.

The pharmaceutical formulations of the present invention include an effective amount of biologically active agent. An effective amount of a biologically active agent is a therapeutically, prophylactically or diagnostically effective amount, which can be determined by a person of ordinary skill in the art taking into consideration factors such as route of  
25 administration; body weight; age; physical condition; therapeutic, prophylactic or diagnostic goal; and type of biologically active agent.

In the case of polymer-based formulations, the type of polymer used, initial burst and subsequent release levels desired, and desired release rate can also influence the amount of a

biologically active agent that produces the desired effect. Initial and subsequent release levels, as well as release rates, are known for a number of polymeric matrices. These parameters can also be determined empirically by comparative in vitro tests of polymeric matrices containing different concentrations of one or more biologically active agents.

- 5 Typically, a polymeric matrix intended to modulate the release of a biologically active agent contains from about 0.01 percent (w/w) biologically active agent to about 50 percent biologically active agent (w/w).

Where the biologically active agent is a polypeptide, preferred pharmaceutical formulations of the invention include a metal cation component. In polymer-based  
10 formulations, the metal cation component is preferably mixed with the agent prior to addition to the polymeric matrix. The metal cation component is selected such that it modulates the release of the polypeptide from the polymeric matrix. A suitable metal cation component has at least one kind of multivalent metal cation (having a valence of +2 or more) in a non-dissociated state, a dissociated state, or a combination of non-dissociated and dissociated  
15 states. Suitable metal cation components include, for instance, metal salts, metal hydroxides, and basic (pH of about 7.0 or higher) salts of weak acids, wherein the salt contains a metal cation. An exemplary metal cation component is zinc derived from zinc acetate (See Example 1.)

Pharmaceutical formulations according to the invention are produced by adding the  
20 particulate/biologically active agent component(s) to an injection vehicle according to the invention. For polymer-based formulations, polymeric microparticles including the biologically active agent are added to the injection vehicle.

To form such polymeric microparticles, a suitable polymer is dissolved in a solvent to form a polymer solution. Examples of suitable solvents include, for instance, polar organic  
25 solvents such as methylene chloride, dichloromethane, chloroform, tetrahydrofuran, dimethyl sulfoxide, and hexafluoroisopropanol. Suitable polymer solutions generally contain about 5 percent to about 30 percent polymer (w/v). In a more preferred embodiment, the polymer solution contains about 5 to about 15 percent polymer (w/v).



At least one biologically active agent is dispersed within the polymer solution. The biologically active agent can be dispersed by any suitable method that produces a relatively homogeneous suspension or solution, including sonication, mixing, and homogenization. A biologically active agent can be added directly to the polymer solution as a solid, preferably in particulate form. In the latter case, the biologically active agent typically becomes suspended as solid particles dispersed within the polymer solution. In some embodiments, before addition to a polymer solution, the biologically active agent is conveniently suspended as solid particles or dissolved in a second solvent, and the resulting solution is then added to the polymer solution. The second solvent can be the same as first solvent (i.e., that used to dissolve the polymer) or, alternatively, can be a different solvent, provided the second solvent is miscible with the first solvent, and the polymer is soluble in the second solvent. An example of a suitable second solvent is acetone. Those skilled in the art appreciate that the biologically active agent can also be suspended or dissolved in a solvent, after which, a suitable polymer or polymer solution is added to the biologically active agent suspension or solution.

In a preferred embodiment, a metal cation component is added to the polymer solution. The metal cation component and biologically active agent can be added to the polymer solution sequentially, in reverse order, intermittently, or through separate, concurrent additions. In one embodiment, the metal cation component is dissolved in a solvent, which is also suitable for the polymer and then mixed into the polymer solution. Alternatively, the biologically active agent can be added to a metal cation component suspension or solution (or vice versa), followed by addition of the polymer.

The metal cation component is employed in a concentration that modulates the release of a biologically active agent. The concentration selected depends upon the polymer, the metal cation component, and the biologically active agent utilized. In one embodiment, a metal cation component is dispersed in the polymeric matrix at a concentration between about 0.5 percent and about 30 percent (w/w). In a preferred embodiment, the metal cation component concentration is between about 1 percent (w/w) and about 10 percent (w/w).

The polymeric matrix of this invention can be formed into any shape suitable for injections, such as a microparticle. A microparticle can have a spherical (i.e., generally rounded), non-spherical or irregular shape. However, the preferred microparticle shape is a sphere. Preferred microparticles have an average diameter of between about 5 and about 200 microns.

A microparticle can be produced from polymeric solutions such as those described above by any of a number of available methods. Suitable methods for forming a microparticle from a polymer solution are described in U.S. Patent 5,019,400 issued to Gombotz et al.; PCT Application No. PCT/US95/05511, Publication No. WO 95/29664; and in Example 1. In another embodiment, microparticles are prepared by the solvent evaporation method described in U.S. Patent No. 3,737,337, issued to Schnoring et al.; U.S. Patent No. 3,523,906, issued to Vrancken et al.; U.S. Patent No. 3,691,090, issued to Kitajima et al.; or U.S. Patent No. 4,389,330, issued to Tice et al. Other exemplary methods for forming microparticles are described in U.S. Patent No. 5,643,605, issued to Cleland et al.

In the solvent evaporation method, a polymer solution, which contains a dispersed biologically active agent, and optionally a dispersed metal cation component, is mixed with a continuous phase, in which the polymer solution is substantially immiscible, to form an emulsion. The continuous phase is usually an aqueous solvent. Emulsifiers are often included in the continuous phase to stabilize the emulsion. The polymer's solvent is then evaporated over a period of several hours or more, thereby solidifying the polymer to form a polymeric matrix in microparticle form.

Pharmaceutical formulations according to the invention can include other components, such as a physiologically acceptable excipient or stabilizer. A physiologically acceptable excipient, or stabilizer suitable for use in the invention is non-toxic to recipients at the dosages employed, and can include an antioxidant (e.g., ascorbic acid), a low-molecular weight (less than about 10 residues) polypeptide, a protein (such as serum albumin, gelatin, and an immunoglobulin), a hydrophilic polymer (such as polyvinylpyrrolidone), an amino acid (such as glycine, glutamine, asparagine, arginine, and lysine), a monosaccharide, a disaccharide,

polysaccharide and other carbohydrates (including glucose, mannose, dextrans, celluloses and methylcellulose), a chelating agent (e.g., ethylenediaminetetracetic acid [EDTA]), a sugar alcohol (such as mannitol and sorbitol), a salt-forming counterion (e.g., sodium), a metal cation (e.g., zinc), an anionic surfactant (such as Tween<sup>TM</sup>, Pluronic<sup>TM</sup>, and PEG) and/or a  
5 preservative (e.g., those containing quaternary ammonium salts, such as benzethonium chloride).

Excipients or stabilizers can be dispersed within a polymeric matrix as described above for the optional metal cation component, provided that any such excipient or stabilizer does not significantly interfere with the formation of the polymeric matrix. Excipients or  
10 stabilizers can also be added to the injection vehicle.

Preferred sustained-release formulations for polypeptides can include polypeptides attached, typically via  $\epsilon$ -amino groups, to a polyalkylene glycol (e.g., polyethylene glycol [PEG]). Attachment of PEG to proteins is a well-known means of reducing immunogenicity and extending in vivo half-life (see, e.g., Abuchowski, J., et al. (1977), J. Biol. Chem.  
15 252:3582-86). Any conventional "pegylation" method can be employed, provided the "pegylated" polypeptide retains at least one biological activity.

Pharmaceutical formulations of the invention can be stored in any standard form, including, for example, an aqueous solution or a lyophilized cake. Such formulations are typically sterile when administered to recipients. Sterilization of an aqueous solution is  
20 readily accomplished by filtration through a sterile filtration membrane. If the formulation is stored in lyophilized form, the formulation can be filtered before lyophilization and reconstitution.

The invention also provides articles of manufacture including injection vehicles and formulations according to the invention as well as related kits. The invention encompasses  
25 any type of article including an injection vehicle or formulation of the invention, but the article of manufacture is typically a container, preferably bearing a label identifying the injection vehicle or formulation contained therein. The container can be formed from any material that does not react with the contained injection vehicle or formulation and can have

any shape or other feature that facilitates use of the injection vehicle or formulation for the intended application. A container for an injection vehicle or pharmaceutical formulation of the invention generally has a sterile access port, such as, for example, an intravenous solution bag or a vial having a stopper pierceable by a hypodermic injection needle.

- 5           Kits of the invention generally include one or more such articles of manufacture and preferably include instructions for use.

#### Administration of Polymeric Formulations

- 10           The formulations of this invention can be administered to an animal, preferably a mammal, more preferably a human, by injection. Suitable routes of administration include, for example, intravenous, intraperitoneal, intracerebral, intramuscular, intraocular, intravitreal, intraarterial, subcutaneous, or intralesional routes. Pharmaceutical formulations of the invention can be administered continuously by infusion, by bolus injection, or by any injection method appropriate for the particular preparation.

- 15           The needle employed for injection should have a bore size that allows injection of the desired dose of the pharmaceutical formulation. Generally, a 23 gauge needle provides good injectability of polymer-based formulations, but smaller (e.g., 24, 25, 26, 27, and 28 gauge) needles are preferred to reduce the pain of injection.

- 20           Dosages for pharmaceutical formulations according to the invention depend on a variety of considerations, such as the therapeutic objectives, the route of administration, and the condition of the recipient, and the maximum dose that can be administered by injection. Accordingly, it is necessary for the clinician to titer the dosage and modify the route of administration as required to obtain the optimal therapeutic effect. A typical daily dosage can range from about 1  $\mu\text{g/kg}$  up to about 100 mg/kg of body weight or more per day, but is
- 25           typically between about 10  $\mu\text{g/kg/day}$  to 10 mg/kg/day. Generally, the clinician begins with a low dosage of a pharmaceutical formulation and increases the dosage until the desired therapeutic effect is achieved.

The administration of a pharmaceutical formulation of the invention can be combined with other therapeutic regimens. For the treatment of cancer, radiation and/or a chemotherapeutic agent can be administered concomitantly with a pharmaceutical formulation of the invention. Suitable preparation and dosing schedules for chemotherapeutic agents are as recommended by the manufacturer or as determined empirically by the clinician. Preparation and dosing schedules for standard chemotherapeutic agents are found in Chemotherapy Service Perry ed., (Williams & Wilkins (1992)). The chemotherapeutic agent can be administered before, after, or simultaneously with administration of the pharmaceutical formulation. Antibodies against tumor-associated antigens, such as antibodies that bind EGFR, ErbB-2, ErbB-3, or ErbB-4 receptor, or vascular endothelial growth factor (VEGF) can also be co-administered with a pharmaceutical formulation(s) of the invention, as can one or more cytokines.

## EXAMPLES

### Example 1

Recombinant human growth hormone (rhGH) was encapsulated into PLGA microspheres using a cryogenic, non-aqueous process described by Gombotz et al., U.S. Patent No. 5,019,400, issued in 1991. To stabilize rhGH, the protein was formulated with zinc acetate to produce a sparingly soluble Zn:rhGH complex. Zinc was chosen because histochemical evidence indicated that hGH is stored in the pituitary as a zinc complex. In addition, rhGH complexed with zinc was known to be more resistant than uncomplexed rhGH to denaturation with guanidine hydrochloride.

Eleven different microsphere formulations were made for initial evaluation. The variables that were investigated were polymer molecular weight (10 kD, 8 kD, and 31 kD), polymer end group (capped or uncapped), and the amount of zinc carbonate (0, 1, 3, and 6 %) added as an excipient. The zinc carbonate excipient was included to act as a depot for zinc

ions to ensure that rhGH remained complexed to zinc. The molar ratio of lactide to glycolide in all polymers was kept constant at 50:50, and the molar ratio of Zn:rhGH in all microsphere formulations investigated was 6:1. All microsphere formulations were prepared using D,L-PLGA obtained either from Birmingham Polymers (Birmingham, AL; #115-56-1; 0.2dL/g, 10kD, dodecanyl end group [i.e., capped,]) or from Boehringer Ingelheim (Ingelheim, Germany; RG502H; 0.2dL/g, 8kD; and RG503H; 0.4dL/g, 31kD, both of which had a carboxylic and acid end group [i.e., uncapped]).

Microspheres were produced as described in Johnson, O., et al.; *Pharmaceutical Research*, "The Stabilization and Encapsulation of Human Growth Hormone into Biodegradable Microspheres," Vol. 14, No. 6 (1997). Briefly, rhGH was first formulated into a lyophilized powder, and the lyophilized powder was then encapsulated into the microspheres. Lyophilized powder was prepared by mixing solutions of rhGH (Nutropin, Genentech, Inc.) with zinc acetate to achieve a molar ratio of 6:1 zinc acetate:rhGH. The Zn:rhGH dispersion was atomized through an ultrasonic nozzle into liquid nitrogen, and the frozen droplets were lyophilized.

The polymer suspension was sprayed through a sonicating nozzle into a vessel containing frozen ethanol overlaid with liquid nitrogen. The vessel was then transferred to -80°C, where the ethanol melted, and the microspheres hardened as the dichloromethane was extracted by the ethanol. After 3 days, the microspheres were harvested by filtration, dried under vacuum, and sieved through a 106 µm mesh screen.

## Example 2

### *Analysis of rhGH Microspheres*

The eleven microsphere formulations of Example 1 were analyzed using a variety of techniques. Microspheres were placed on an aluminum stub and sputter coated with a layer of carbon or gold and imaged using a JEOL model 6400 scanning electron microscope. The mean particle diameter distribution of the microspheres was determined using a Coulter Multisizer. The rhGH load of the microspheres was determined by nitrogen analysis.



Approximately 95% of protein was encapsulated into microspheres, which had a mean volume diameter of about 50 microns.

In addition, the physical and biological integrity of the rhGH recovered from the microspheres was analyzed by size exclusion (SEC), reversed-phase, and anion-exchange chromatography. These techniques were used to detect aggregated, oxidized, and deamidated rhGH respectively. For these analyses, rhGH was recovered from the microspheres using two different methods. In the first, the microspheres were dissolved in a mixture of methylene chloride and acetone, and the protein precipitate was collected. In the second, the protein was recovered by incubating the microspheres in HEPES buffer.

Chromatography was done according to published methods (Teshima, G., and Canoval-Davis, E. (1991), *J. Biol. Chem.* 266:13544-47; Battersby, J.E., et al. (1992), *J. of Chromatog.* 625:2007-15; Battersby, J.E., et al. (1995) *Anal. Chem.* 67:447-55; Canova-Davis, E., et al. (1990), *Int. J. Peptide Protein Res.* 35:17-24). Briefly, SEC was performed on a G2000SW XL TSK Gel Column with phosphate buffer as the mobile phase. rhGH was detected by UV absorption at 214 nm. Reversed-phase chromatography was carried out on a polymeric reversed-phase column using acetonitrile gradient elution at 50°C. Ion-exchange chromatography was performed on a DEAE-5PW TSK Gel Column with a phosphate and acetonitrile gradient elution. For the reversed phase and ion-exchange methods, rhGH was detected by fluorescence, with excitation at 286 nm and emission at 335 nm.

Finally, rhGH bioactivity was determined in a cell proliferation assay using a cell line that expresses the receptor for hGH and proliferates in the presence of hGH (see Roswall, E.C., et al. (1996) *Biologicals* 24:25-39). Cell proliferation was measured by conversion of Alamar Blue dye to a fluorescent product by intracellular reductases. Fluorescence is proportional to the number of cells. rhGH-containing samples were incubated with cells for 72 hours at 37°C, and fluorescence, was quantitated.

The rhGH recovered from each of the formulations was essentially monomeric, indicating that there was no effect of the formulation variables tested on protein aggregation. The analysis of rhGH integrity indicated that there were no significant differences between the

protein before and after encapsulation. In addition, the specific bioactivity of the protein released from all formulations analyzed was similar to that of the unencapsulated standard. Furthermore, SDS-reducing gel electrophoresis and HPLC analysis of a tryptic digest of one of the formulations revealed that the extracted protein was comparable to unencapsulated protein. Taken together, these data show that rhGH is essentially unaltered after extraction or release from microspheres after extended incubation at physiological temperatures.

### Example 3

#### *Syringeability Study of an anti-VEGF Fab Polymer-Based Formulation*

##### *Containing Sodium Hyaluronate (Amvisc® Plus)*

An injection vehicle was prepared by diluting Amvisc® Plus (Chiron Vision Corporation, Claremont, CA, USA) in 0.9% Sodium Chloride USP.

Amvisc® Plus is supplied in a disposable glass syringe delivering either 0.4 mL or 0.8 mL of 1.6% sodium hyaluronate (w/v) in physiological saline. Each mL of Amvisc® Plus contains 16 mg of sodium hyaluronate, 9 mg NaCl dissolved in sterile water for injection (SWFI USP). Amvisc® Plus was diluted to 0.05%, 0.1%, 0.2%, 0.4%, 0.6%, and 0.8% (i.e., 0.5, 1, 2, 4, 6, and 8 mg/ml).

The injection vehicles were mixed with anti-VEGF Fab PLGA microspheres prepared as described in Example 1 to produce formulations containing 100 mg/mL anti-VEGF Fab PLGA microspheres (lot 96-22-195-1).

These formulations were tested for syringeability by injecting 1 mL of each formulation into tubes using 23, 24, 25, 27, and 28 gauge needles. 1 mL of each formulation was readily injectable through all needles tested.

A similar polymer-based formulation using a 3.0 % (w/v) solution of the linear carbohydrate carboxymethyl cellulose (CMC) as the injection vehicle required a 21 gauge needle for injection of a 100 mg/mL dose.



#### Example 4

##### *Syringeability Study of Various Polymer-Based Formulations*

##### *Containing Sodium Hyaluronate (Amvisc® Plus)*

An injection vehicle was prepared by diluting Amvisc® Plus (Chiron Vision Corporation, Claremont, CA, USA) in 0.9% Sodium Chloride USP to 0.05%, 0.1%, 0.15%, and 0.2% (w/v).

To produce polymer-based formulations, the injection vehicle was mixed with Nutropin Depot®, VEGF microspheres, VEGF/heparin microspheres, and NGF microspheres. These microsphere preparations were prepared as described in Example 1. The microsphere concentrations are given in Table 1.

These formulations were tested for syringeability by injecting 1 mL of each formulation into tubes using 23, 24, 25, 27, and 28 gauge needles. The results of this study are shown in Table 1, which indicates the smallest gauge needle that could be used to inject 1 mL of each formulation.

Table 1

Products Tested	Amvisc <sup>®</sup> Plus Concentration			
	0.05%	0.1%	0.15%	0.2%
Nutropin Depot <sup>®</sup> (lot ASO-b, 125 mg/mL, Alkermes)	≤25G*	≤24G	≤24G	≤24G
VEGF microspheres (lot VEGF-18, 100 mg/mL, Genentech)	≤24G	≤24G	≤24G	≤23G
VEGF/heparin microspheres (lot VEGF- 22, 100 mg/mL, Genentech)	≤24G	≤24G	≤24G	≤23G
NGF microspheres (lot NGF-14, 100 mg/mL, Genentech)	≤25G	≤25G	≤24G	≤24G

\* Indicates that the formulation could be injected through 25 gauge or larger (smaller G)  
5 needles.

### Example 5

#### *Syringeability Study of Various Polymer-Based formulations Containing Sodium Hyaluronate (Hylumed<sup>®</sup>)*

10 An injection vehicle containing sodium hyaluronate was prepared by diluting  
Hylumed<sup>®</sup> (Genzyme Pharmaceuticals, Cambridge, MA, USA) to 0.01% and 0.10% in 0.9%  
Sodium Chloride USP. For comparison, a second vehicle containing 3% (w/v)  
carboxymethylcellulose (CMC) in 0.9% Sodium Chloride USP was also prepared.

The injection vehicles were mixed with the microsphere preparations indicated in  
15 Table 2, which were prepared as described in Example 1. The microsphere concentrations are  
given in Table 2.

These formulations were tested for syringeability by injecting 1 mL of each formulation into tubes using 21, 22, 23, 24, 25, 26 and 27 gauge needles. The results of this study are shown in Tables 2 and 3, which indicates the smallest gauge needle that could be used to inject each formulation. Table 3 indicates that when the microsphere concentration is doubled for formulations containing 0.10% Hylumed<sup>®</sup>, a small (24G) gauge needle can be employed for injection. Thus, a smaller gauge needle can be used to inject twice as many microspheres in one dose as with a conventional CMC-based injection vehicle.

Table 2

10

Products Tested	Hylumed <sup>®</sup> Conc.		CMC Conc.
	0.01%	0.10%	3.0%
Nutropin Depot <sup>®</sup> (lot ASO-b, 125 mg/mL, Alkermes)	≤24G*	≤25G	≤22G
Nutropin Depot <sup>®</sup> (lot 3000511, 125 mg/mL, Alkermes)	≤24G	≤25G	≤22G
Nutropin Depot <sup>®</sup> (lot 541a, 125 mg/mL, Alkermes)	≤24G	≤24G	≤22G
VEGF microspheres (lot VEGF-20, 100 mg/mL, Genentech)	≤24G	≤25G	≤22G

\*Indicates that the formulation could be injected through 24 gauge or larger (smaller G) needles.

Table 3

Products Tested	Hylumed <sup>®</sup> Concentration 0.10%
Nutropin Depot <sup>®</sup> (lot ASO-b, 250 mg/mL, Alkermes)	≤24G <sup>*</sup>
Nutropin Depot <sup>®</sup> (lot 3000511, 250 mg/mL, Alkermes)	≤24G
Nutropin Depot <sup>®</sup> (lot 541a, 250 mg/mL, Alkermes)	≤24G
VEGF microspheres (lot VEGF-20, 200 mg/mL, Genentech)	≤24G

5      <sup>\*</sup>Indicates that the formulation could be injected through 25 gauge or larger (smaller G) needles.

#### Example 6

##### *Suitability of Various Macromolecules For Use in an Injection Vehicle for Polymer-Based Microspheres*

10            Solutions of the following macromolecules in 0.9% Sodium Chloride USP were  
prepared for use as injection vehicles for polymer-based microspheres: sodium alginate  
(Kelco Co., San Diego, CA, USA), aggrecan (Sigma Chemical Co., St. Louis, MO, USA),  
dextran 70 (Sigma Chemical Co., St. Louis, MO, USA), jeffamine M-600 (Hampton Res.,  
Laguna Niguel, CA, USA), jeffamine ED-2001 (Hampton Res., Laguna Niguel, CA, USA),  
15    keretan sulphate (Sigma Chemical Co., St. Louis, MO, USA), laminin (Sigma Chemical Co.,  
St. Louis, MO, USA), poly-L-ornithine (Sigma Chemical Co., St. Louis, MO, USA), xanthan

gum (Sigma Chemical Co., St. Louis, MO, USA), and gellan gum (Sigma Chemical Co., St. Louis, MO, USA).

Concentrations tested ranged from 0.01% - 1.0% (w/v). Nutropin Depot<sup>®</sup> microspheres, prepared as described in Example 1, were added to a final concentration of 125 mg/mL.

These formulations were tested for syringeability by injecting 1 mL of each formulation into tubes using 21, 22, 23, 24, 25, 26 and 27 gauge needles. The results of this study indicated that a 21G needle is the smallest gauge needle that could be used to inject 1 mL of each formulation. Thus, none of the vehicles tested were superior to conventional CMC-based vehicles.

### Example 7

#### *Intravitreal Injectability Study of Polymer-Based Formulations Containing Anti-VEGF Fab in Sodium Hyaluronate*

Two injection vehicles were prepared, the first, from Amvisc<sup>®</sup> Plus (Chiron Vision Corporation, Claremont, CA, USA) and the second, from sodium hyaluronate obtained from Sigma Chemical Company, (St. Louis, MO). Both were diluted to 0.1% (w/v) sodium hyaluronate in 0.9% Sodium Chloride USP.

To produce polymer-based formulations, each injection vehicle was mixed with anti-VEGF Fab microspheres (100 mg/mL). The microspheres were prepared as described in Example 1.

These formulations were tested for intravitreal injectability into the eyes of rabbits. 50 µL of each formulation was readily injectable using a 30 gauge needle. No significant inflammation was observed in the rabbits' eyes 24 hours after injection.

The present invention has of necessity been discussed herein by reference to certain specific methods and materials. It is to be understood that the discussion of these specific methods and materials in no way constitutes any limitation on the scope of the present invention, which extends to any and all alternative materials and methods suitable for accomplishing the ends of the present invention.

\*\*\*\*\*

All references cited herein are expressly incorporated by reference.

RECEIVED

What is claimed is:

1. An injection vehicle comprising hyaluronic acid or a derivative thereof at a concentration of about 0.01 to about 0.8 percent by volume.
2. The injection vehicle of Claim 1, wherein the injection vehicle comprises hyaluronic acid.
3. The injection vehicle of Claim 1, wherein the hyaluronic acid or derivative thereof is dissolved in physiological saline.
4. A pharmaceutical formulation comprising:
  - (a) an effective amount of a biologically active agent in particulate form or coated on, dispersed within, or accompanied by particles; and
  - (b) an injection vehicle comprising hyaluronic acid or a derivative thereof.
5. The pharmaceutical formulation of Claim 4 wherein the biologically active agent dispersed within particles comprising a biocompatible polymeric matrix.
6. The pharmaceutical formulation of Claim 5, wherein the injection vehicle comprises hyaluronic acid.
7. The pharmaceutical formulation of Claim 6, wherein the concentration of hyaluronic acid is between about 0.01 and about 0.8 percent weight per volume.
8. The pharmaceutical formulation of Claim 6, wherein the hyaluronic acid is dissolved in physiological saline.
9. The pharmaceutical formulation of Claim 6, wherein the polymer matrix comprises a polymer selected from the group consisting of a biodegradable polymer, a non-

biodegradable polymer, a mixture of biodegradable and non-biodegradable polymers, and a copolymer comprising biodegradable and non-biodegradable units.

10. The pharmaceutical formulation of Claim 6, wherein the polymeric matrix comprises a polymer selected from the group consisting of blocked polymers, unblocked polymers, and mixtures thereof.

11. The pharmaceutical formulation of Claim 6, wherein the polymeric matrix comprises a polymer selected from the group consisting of a poly(glycolide); a poly(lactide-co-glycolide); a poly(lactic acid); a poly(glycolic acid); a poly(lactic acid-co-glycolic acid); a polyanhydride; a polyorthoester; a polyetherester; a polycaprolactone; a polyesteramide; a block copolymer of polyethylene glycol and lactide or glycolide; and a blend or copolymer thereof.

12. The pharmaceutical formulation of Claim 11, wherein the polymer is a poly(lactide-co-glycolide) polymer.

13. The pharmaceutical formulation of Claim 6, wherein the biologically active agent is a polypeptide.

14. The pharmaceutical formulation of Claim 11, wherein the polypeptide is selected from the group consisting of a growth hormone, a hepatocyte growth factor (HGF), a vascular endothelial growth factor (VEGF), an anti-vascular endothelial growth factor Fab (anti-VEGF Fab), a glucagon-like peptide I (GLP-I), a nerve growth factor, and an insulin-like growth factor.

15. The pharmaceutical formulation of Claim 6, wherein the concentration of the polymeric matrix comprising the biologically active agent is between at least about 1 mg/mL to about 500 mg/mL of formulation.

16. The pharmaceutical formulation of Claim 15, wherein the concentration of the polymeric matrix comprising the biologically active agent is between at least about 1 mg/mL to about 300 mg/mL of formulation.



17. A pharmaceutical formulation comprising:
  - (a) particles comprising a biocompatible polymeric matrix comprising a poly(lactide-co-glycolide) polymer;
  - (b) an effective amount of a biologically active polypeptide dispersed within the polymeric matrix; and
  - (c) an injection vehicle comprising hyaluronic acid or a derivative thereof.
18. A method for producing a pharmaceutical formulation comprising:
  - adding an effective amount of a biologically active agent in particulate form or coated on, dispersed within, or accompanied by particles
  - to an injection vehicle comprising hyaluronic acid or a derivative thereof.
19. The method of Claim 18 wherein the injection vehicle comprises hyaluronic acid.
20. A method for administering a pharmaceutical formulation of Claim 17 comprising injecting the pharmaceutical formulation through a 23-gauge or smaller needle.

## ABSTRACT OF THE DISCLOSURE

The invention provides injection vehicles suitable for administering particulate suspensions, such as polymer-based formulations, as well as associated pharmaceutical formulations, articles of manufacture, and kits. Other aspects of the invention included methods for producing and administering pharmaceutical formulations. The injection vehicles of the invention are superior to conventional injection vehicles in that they include a pseudoplastic composition that improves injectability, which facilitates delivery of the desired dose. The injection vehicles of the invention also allow the use of smaller-bore needles than are usually necessary to inject polymer-based formulations, reducing the pain associated with injection of such formulations.

# DECLARATION FOR PATENT APPLICATION AND POWER OF ATTORNEY

As a below named inventor, I hereby declare that:

My residence, post office address and citizenship are as stated below adjacent to my name.

I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of subject matter (process, machine, manufacture, or composition of matter, or an improvement thereof) which is claimed and for which a patent is sought by way of the application entitled

## INJECTION VEHICLE FOR POLYMER-BASED FORMULATIONS

which (check) ☒ is attached hereto.  
☐ and is amended by the Preliminary Amendment attached hereto.  
☐ was filed on      as Application Serial No.  
☐ and was amended on      (if applicable).

I hereby state that I have reviewed and understand the contents of the above identified specification, including the claims, as amended by any amendment referred to above.

I acknowledge the duty to disclose information, which is material to patentability as defined in Title 37, Code of Federal Regulations, § 1.56.

I hereby claim foreign priority benefits under Title 35, United States Code, § 119(a)-(d) of any foreign application(s) for patent or inventor's certificate or any PCT international application(s) designating at least one country other than the United States of America listed below and have also identified below any foreign application(s) for patent or inventor's certificate or any PCT international application(s) designating at least one country other than the United States of America filed by me on the same subject matter having a filing date before that of the application(s) of which priority is claimed:

Prior Foreign Application(s)			Priority Claimed	
Number	Country	Day/Month/Year Filed	Yes	No
N/A			<input type="checkbox"/>	<input type="checkbox"/>

I hereby claim the benefit under Title 35, United States Code, § 119(e) of any United States provisional application(s) listed below:

Provisional Application Number	Filing Date
60/159,739	October 15, 1999

I hereby claim the benefit under Title 35, United States Code, § 120 of any United States application(s) or PCT international application(s) designating the United States of America listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior application(s) in the manner provided by the first paragraph of Title 35, United States Code, § 112, I acknowledge the duty to disclose information, which is material to patentability as defined in Title 37, Code of Federal Regulations, § 1.56, which became available between the filing date of the prior application(s) and the national or PCT international filing date of this application:

Application Serial No.	Filing Date	Status (patented, pending, abandoned)
N/A		{Status}

I hereby appoint the following attorney(s) and/or agent(s) to prosecute this application and to transact all business in the United States Patent and Trademark Office connected therewith:


Alan H. MacPherson (24,423); Brian D. Ogonowsky (31,988); David W. Heid (25,875); Norman R. Klivans (33,003); Edward C. Kwok (33,938); David E. Steuber (25,557); Michael Shenker (34,250); Stephen A. Terrile (32,946); Peter H. Kang (40,350); Ronald J. Meetin (29,089); Ken John Koestner (33,004); Omkar K. Suryadevara (36,320); David T. Millers (37,396); Michael P. Adams (34,763); Robert B. Morrill (43,817); James E. Parsons (34,691); Philip W. Woo (39,880); Emily Haliday (38,903); Tom Hunter (38,498); Michael J. Halbert (40,633); Gary J. Edwards (41,008); Daniel P. Stewart (41,332); Tom Chen (42,406); Fabio E. Marino (43,339); Don C. Lawrence (31,975); Marc R. Ascolese (42,268); Carmen C. Cook (42,433); David G. Dolezal (41,711); Roberta P. Saxon (43,087); Mary Jo Bertani (42,321); Dale R. Cook (42,434); Sam G. Campbell (42,381); Matthew J. Brigham (44,047); Shireen Irani Bacon (40,494); Rory G. Bens (44,028); George Wolken, Jr. (30,441); John A. Odozynski (28,769); Paul E. Lewkowicz (44,870); Theodore P. Lopez (44,881); Eric Stephenson (38,321); Christopher Allenby (45,906); David C. Hsia (46,235); Mark J. Rozman (42,117); Margaret M. Kelton (44,182); Do Te Kim (46,231); Alex Chen (45,591); Monique M. Heyninck (44,763); Gregory J. Michelson (44,940); Jonathan Geld (44,702); Emmanuel Rivera (45,760); Jason FarHadian (42,523); Matthew J. Spark (43,453); Elaine H. Lo (41,158); Jon Hallman (42,622); Robert Strawbrich (36,692); Rita M. Wisor (41,382); Gregory Powell (47,005); and Mark E. Schmidt (47,063).

Please address all correspondence and telephone calls to:

Emily M. Haliday  
**SKJERVEN MORRILL MacPHERSON LLP**  
 25 Metro Drive, Suite 700  
 San Jose, California 95110-1349

Telephone: 408-453-9200  
 Facsimile: 408-453-7979

I declare that all statements made herein of my own knowledge are true, all statements made herein on information and belief are believed to be true, and all statements made herein are made with the knowledge that whoever, in any matter within the jurisdiction of the Patent and Trademark Office, knowingly and willfully falsifies, conceals, or covers up by any trick, scheme, or device a material fact, or makes any false, fictitious or fraudulent statements or representations, or makes or uses any false writing or document knowing the same to contain any false, fictitious or fraudulent statement or entry, shall be subject to the penalties including fine or imprisonment or both as set forth under 18 U.S.C. 1001, and that violations of this paragraph may jeopardize the validity of the application or this document, or the validity or enforceability of any patent, trademark registration, or certificate resulting therefrom.

Full name of first joint inventor: Jeffrey L. Cleland  
 Inventor's Signature:   
 Residence: San Carlos, California  
 Post Office Address: 225 Aberdeen Drive  
 San Carlos, CA 94070

Date:

10/10/00

Citizenship: U.S.

Full name of second joint inventor: Xanthe M. Lam

Inventor's Signature: Xanthos Lann

Date: 10-10-00

Residence: South San Francisco, California

Post Office Address: 662 Orchid Drive  
South San Francisco, CA 94080

Citizenship: U.S.

Full name of third joint inventor: Franklin Okumu

Inventor's Signature: 

Date: 11 OCT 00

Residence: Oakland, California

Post Office Address: 3882 Shafter Avenue  
Oakland, CA 94609

Citizenship: U.S.